US Supreme Court is asked to rule on validity of patents on BRCA1 and BRCA2 genesBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e6624 (Published 02 October 2012) Cite this as: BMJ 2012;345:e6624
- Clare Dyer
The US Supreme Court has been asked to review the validity of patents on isolated human genes associated with breast and ovarian cancer, which campaigners and medical groups said stifle research and hamper women’s access to care.
The American Civil Liberties Union (ACLU) and the Public Patent Foundation have filed a brief with the court asking it to look at whether patents held on BRCA1 and BRCA2 by a Utah company, Myriad Genetics, are valid.
“Laws of nature” and “products of nature” are not patentable under US law, and the ACLU has …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial